By: IPP Bureau
Last updated : October 06, 2026 8:51 am
The two-day event in Mumbai featured 75+ speakers, 30+ panel discussions and 20+ exhibitors, with focus on spanning peptides, complex generics, oligonucleotides, regulatory pathways, artificial intelligence in drug development and more
The 2nd edition of the Peptides & Complex Generics Symposium (PCG 2026), hosted by Mumbai Biocluster, an initiative of the Institute of Chemical Technology (ICT), Mumbai, concluded on September 29, bringing together 400+ stakeholders from the pharmaceutical, biotechnology, academic, regulatory and technology sectors.
The two-day symposium featured 75+ speakers, 30+ panel discussions and 20+ exhibitors, with discussions spanning peptides, complex generics, oligonucleotides, manufacturing, regulatory pathways, drug delivery, analytical characterisation and artificial intelligence in drug development.
The opening plenary, “Billion Dose Challenge: Can India Scale Without Compromising Quality?”, brought together representatives from CDSCO, Dr. Reddy’s Laboratories, Novo Nordisk and Bharat Serums and Vaccines to examine the growing demand for peptide and GLP-1 therapeutics and the manufacturing capabilities needed to support large-scale production.
The session was moderated by Dr. Ratnesh Jain, Founder & Director, Mumbai Biocluster and Convenor, PCG Symposium.
A separate plenary examined global pharmaceutical supply-chain resilience beyond the China+1 strategy, bringing together industry leaders to discuss supply diversification, API security, manufacturing competitiveness and India's role in global pharmaceutical value chains.
The panel was moderated by Salil Kallianpur, Founder & MD, ARKS Knowledge Consulting Pvt. Ltd., and featured Bharat Shah, MD, S Kant Healthcare Ltd. and National President, IDMA; Namit Joshi, Chairman, Pharmexcil; Gunjan Singh, CEO, API Plus, Cohance Lifesciences Ltd.; and Dr. Rohtash Kumar, Head of CDMO, Small & Large Molecules, Syngene International Ltd.
The programme also covered peptide synthesis and scale-up, regulatory pathways, drug-delivery technologies and emerging manufacturing challenges. An FDA-focused fireside discussion examined recommendations around product-specific guidance for generic peptides, oral peptides and oligonucleotides.
Day Two expanded the symposium's focus to oligonucleotide therapeutics, with sessions covering manufacturing scale-up, analytical characterisation, bioassays and immunogenicity risk assessment.
Discussions on next-generation drug delivery and oral peptide delivery examined the technologies required to improve the development, manufacturing and delivery of complex therapeutics.
The scientific programme concluded with “AI Advantage: Turning ML into Faster, Smarter Drug Development,”which explored how artificial intelligence and machine learning can accelerate drug discovery and development while improving decision-making across the development lifecycle.
Leadership roundtables and technical workshops
PCG 2026 featured five closed-door leadership roundtables and three specialised workshops focused on cost-of-goods reduction for peptide therapeutics, oligonucleotides from molecular design to market, and peptide purification.
The Leadership Roundtable on Oligonucleotides & ASOs examined scalable purification and regulatory convergence, while highlighting opportunities for India to strengthen its position in the emerging nucleic acid therapeutics CDMO ecosystem.
The global nucleic acid therapeutics CDMO market is projected to reach USD 33.86 billion by 2030, growing at a CAGR of 14.2% between 2025 and 2030, underscoring the scale of the opportunity for companies with specialised capabilities.
The Molecule to Market Expo brought together technology and solution providers supporting the complex therapeutics ecosystem. An interactive gamification initiative encouraged visitors to engage with exhibitors through booth-based quizzes, with scores tracked through a dedicated portal.
The Poster Programme featured 20+ research presentations covering peptides, oligonucleotides, novel drug delivery, next-generation therapeutics, analytical technologies, immunogenicity and computational approaches.
Connecting science, manufacturing and regulation
PCG 2026 provided a platform for scientists, pharmaceutical and biotechnology leaders, regulators, policymakers, technology providers and researchers to exchange perspectives on the development and manufacturing of increasingly complex therapeutics.
The second edition broadened the symposium's scientific scope to include oligonucleotide therapeutics, strengthening discussions around the technologies, manufacturing capabilities and cross-sector collaborations needed to move next-generation therapies from pilot scale to commercial production and from volume to value.
With the rapid evolution of peptide and nucleic acid therapeutics, PCG 2026 highlighted the need for greater collaboration between science, industry, manufacturing and regulatory stakeholders to build scalable and globally competitive capabilities.
The PCG platform will return in 2027, continuing the conversation around peptides, oligonucleotides, complex therapeutics and the technologies shaping their development and commercialisation.